Capricor Therapeutics (CAPR) Misses Q1 EPS by 21c

Capricor Therapeutics (NASDAQ: CAPR) reported Q1 EPS of ($0.53), $0.21 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $0 versus the consensus estimate of $3.79 million.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Macquarie Downgrades Luk Fook Holdings International Ltd. (590:HK) (LKFLF) to Neutral
• onsemi downgraded by TD Cowen after Synaptics deal clouds growth story